158 related articles for article (PubMed ID: 37549559)
1. Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis.
Wenger KJ; Hoelter MC; Yalachkov Y; Hendrik Schäfer J; Özkan D; Steffen F; Bittner S; Hattingen E; Foerch C; Schaller-Paule MA
Eur J Radiol; 2023 Sep; 166():111019. PubMed ID: 37549559
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
[TBL] [Abstract][Full Text] [Related]
4. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
5. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
6. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
[TBL] [Abstract][Full Text] [Related]
8. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
[TBL] [Abstract][Full Text] [Related]
9. The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis.
Adams A; Tilden W; Bestwick J; Holden D; Bianchi L; Smets I; Giovannoni G; Gnanapavan S
Eur J Neurol; 2022 Sep; 29(9):2754-2760. PubMed ID: 35615966
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
[TBL] [Abstract][Full Text] [Related]
11. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
[TBL] [Abstract][Full Text] [Related]
12. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.
Ammitzbøll C; Dyrby TB; Börnsen L; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Lundell H; Jensen PEH; Sørensen PS; Siebner HR; Sellebjerg F
Mult Scler Relat Disord; 2023 Sep; 77():104854. PubMed ID: 37418931
[TBL] [Abstract][Full Text] [Related]
13. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
[TBL] [Abstract][Full Text] [Related]
15. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients.
Midaglia L; Rovira A; Miró B; Río J; Fissolo N; Castilló J; Sánchez A; Montalban X; Comabella M
Eur J Neurol; 2024 Jan; 31(1):e16077. PubMed ID: 37754568
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
[TBL] [Abstract][Full Text] [Related]
17. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
[TBL] [Abstract][Full Text] [Related]
18. Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
Camara-Lemarroy C; Metz L; Kuhle J; Leppert D; Willemse E; Li DK; Traboulsee A; Greenfield J; Cerchiaro G; Silva C; Yong VW
Mult Scler; 2022 Nov; 28(13):2081-2089. PubMed ID: 35848622
[TBL] [Abstract][Full Text] [Related]
19. The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis.
Ercan Z; Bilek F; Demir CF
Mult Scler Relat Disord; 2021 Oct; 55():103219. PubMed ID: 34433118
[TBL] [Abstract][Full Text] [Related]
20. Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS.
Damasceno A; Dias-Carneiro RPC; Moraes AS; Boldrini VO; Quintiliano RPS; da Silva VAPG; Farias AS; Brandão CO; Damasceno BP; Dos Santos LMB; Cendes F
Mult Scler Relat Disord; 2019 May; 30():149-153. PubMed ID: 30772673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]